| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Institute of Medical Microbiology and Hygiene and
Institute of Virology, Johannes Gutenberg-University, Mainz, Germany; and
Rheumatology Section, Imperial College School of Medicine, London, United Kingdom
Besides Ab-independent and Ab-dependent activation of the complement classical pathway in host defense, C1q plays a key role in the processing of immune complexes and in the clearance of apoptotic cells. In humans, C1q deficiency leads to systemic lupus erythematosus-like symptoms in over 90% of the cases, thus making this defect a strong disease susceptibility factor. Similarly, C1q-deficient mice (C1qa-/-) develop systemic lupus erythematosus-like symptoms, such as autoantibodies and glomerulonephritis. We have previously provided evidence that C1q is produced by cells of the monocyte-macrophage lineage. In this study, we have tested whether transplantation of bone marrow cells would be sufficient to reconstitute C1q levels in C1qa-/- mice. C1qa-/- mice received a single graft of 107 bone marrow cells from wild-type (wt) donors after irradiation doses of 6, 7, 8, or 9 Gy. Engraftment was monitored by a Y chromosome-specific PCR and a PCR that differentiated wt from C1qa-/- genotype. Serum levels of C1q Ag and C1 function increased rapidly in the recipient mice, and titers reached normal levels within 6 wk after bone marrow transplantation. In wt mice that received C1qa-/- bone marrow, serum levels of C1q decreased constantly over time and became C1q deficient within 55 wk. These data clearly demonstrate that bone marrow-derived cells are the source of serum C1q and are competent to reconstitute normal C1q serum levels in C1q-deficient mice. Therefore, stem cell transplantation could be a therapy for patients with hereditary C1q deficiency.
This article has been cited by other articles:
|
|
 |
|
  P. Baruah, I. E. Dumitriu, T. H. Malik, H. T. Cook, J. Dyson, D. Scott, E. Simpson, and M. Botto C1q enhances IFN-{gamma} production by antigen-specific T cells via the CD40 costimulatory pathway on dendritic cells Blood, April 9, 2009; 113(15): 3485 - 3493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Baudino, Y. Shinohara, F. Nimmerjahn, J.-I. Furukawa, M. Nakata, E. Martinez-Soria, F. Petry, J. V. Ravetch, S.-I. Nishimura, and S. Izui Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions J. Immunol., November 1, 2008; 181(9): 6664 - 6669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Baudino, F. Nimmerjahn, Y. Shinohara, J.-I. Furukawa, F. Petry, J. S. Verbeek, S.-I. Nishimura, J. V. Ravetch, and S. Izui Impact of a Three Amino Acid Deletion in the CH2 Domain of Murine IgG1 on Fc-Associated Effector Functions J. Immunol., September 15, 2008; 181(6): 4107 - 4112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Paidassi, P. Tacnet-Delorme, V. Garlatti, C. Darnault, B. Ghebrehiwet, C. Gaboriaud, G. J. Arlaud, and P. Frachet C1q Binds Phosphatidylserine and Likely Acts as a Multiligand-Bridging Molecule in Apoptotic Cell Recognition J. Immunol., February 15, 2008; 180(4): 2329 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Castellano, A. M. Woltman, A. J. Nauta, A. Roos, L. A. Trouw, M. A. Seelen, F. P. Schena, M. R. Daha, and C. van Kooten Maturation of dendritic cells abrogates C1q production in vivo and in vitro Blood, May 15, 2004; 103(10): 3813 - 3820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jayne, J. Passweg, A. Marmont, D. Farge, X. Zhao, R. Arnold, F. Hiepe, I. Lisukov, M. Musso, J. Ou-Yang, et al. Autologous stem cell transplantation for systemic lupus erythematosus Lupus, March 1, 2004; 13(3): 168 - 176. [Abstract] [PDF]
|
|
|
|
|
|
A. Verschoor, M. A. Brockman, M. Gadjeva, D. M. Knipe, and M. C. Carroll Myeloid C3 Determines Induction of Humoral Responses to Peripheral Herpes Simplex Virus Infection J. Immunol., November 15, 2003; 171(10): 5363 - 5371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rossbacher and M. J. Shlomchik The B Cell Receptor Itself Can Activate Complement to Provide the Complement Receptor 1/2 Ligand Required to Enhance B Cell Immune Responses In Vivo J. Exp. Med., August 18, 2003; 198(4): 591 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Jaatinen, M. Lahti, O. Ruuskanen, R. Kinos, L. Truedsson, R. Lahesmaa, and M.-L. Lokki Total C4B Deficiency Due to Gene Deletion and Gene Conversion in a Patient with Severe Infections Clin. Vaccine Immunol., March 1, 2003; 10(2): 195 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gadjeva, A. Verschoor, M. A. Brockman, H. Jezak, L. M. Shen, D. M. Knipe, and M. C. Carroll Macrophage-Derived Complement Component C4 Can Restore Humoral Immunity in C4-Deficient Mice J. Immunol., November 15, 2002; 169(10): 5489 - 5495. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
